Evidence map›Paper›PMID 24296266›Full record

ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2014

Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women.

Keimari Mendez, Josefina Romaguera, Ana P Ortiz, Mariel López, Martin Steinau, Elizabeth R Unger

Abstract read
In one paragraph

Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Keimari MendezDepartment of Obstetrics and Gynecology, School of Medicine, University of Puerto Rico, San Juan, USA. Electronic address: keimari.mendez@upr.edu.
Josefina RomagueraDepartment of Obstetrics and Gynecology, School of Medicine, University of Puerto Rico, San Juan, USA.
Ana P OrtizDepartment of Biostatistics and Epidemiology, Graduate School of Public Health, Cancer Control and Population Sciences Program at Comprehensive Cancer Center, University of Puerto Rico, San Juan, USA.
Mariel LópezPuerto Rico Clinical and Translational Research Consortium, University of Puerto Rico, San Juan, USA.
Martin SteinauCenters for Disease Control and Prevention, Atlanta, USA.
Elizabeth R UngerCenters for Disease Control and Prevention, Atlanta, USA.

Funding

TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54MD007587 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI LUCIANO, CARLOS A., NOBOA, CARIAMARIE · 2012 to 2018
$23.2M
TRCLU54RR026139 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FRONTERA, WALTER R. · 2010 to 2011
$8.4M
Hispanic Clinical and Translational Research Education and Career Development ProgramR25MD007607 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Karen G. Martinez Gonzalez, Barbara Segarra-Vazquez · 2012 to 2026
$7.4M
Post-doctoral Master of Science in Clinical ResearchR25RR017589 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ESTAPE, ESTELA S · 2002 to 2011
$5.5M
POSTDOCTORAL MASTER IN CLINICAL RESEARCHR21AR048043 · NIAMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ESTAPE, ESTELA S · 2001 to 2001
$224k
NCRR NIH HHS R25 RR017589NCRR NIH HHS R25RR017589NCRR NIH HHS U54 RR026139NIAMS NIH HHS R21 AR048043NIMHD NIH HHS 8U54MD007587-03NIMHD NIH HHS R25 MD007607NIMHD NIH HHS R25MD007607NIMHD NIH HHS U54 MD007587NIMHD NIH HHS U54MD 007587
6 · The paper itself

Abstract

objectiveTo test the hypothesis that self-collected urine could be used to detect high-risk human papillomavirus (HPV) DNA with sensitivity and specificity comparable to those of standard cervical testing.

methodsWomen attending a gynecology clinic for evaluation of abnormal cytology were recruited. Fifty-two participants (21-60years of age) collected urine samples, and clinicians collected cervical brush samples. When appropriate, cervical biopsies were obtained during colposcopy. HPV detection and typing were performed on DNA extracts from each sample, using commercial reagents for L1 consensus polymerase chain reaction (PCR) and type-specific hybridization. HPV 16 viral load was determined by quantitative PCR in HPV 16-positive samples. A diagnostic test analysis was conducted for urine samples.

resultsFifty paired samples were analyzed, with 76% agreement between samples. The 12 discrepant pairs were all urine negative/cervix positive. The most common HPV types detected were 16, 51, 53, and 62. The urine test correctly identified 100% of the uninfected and 65% of the infected patients.

conclusionThe results indicate that HPV DNA detection using urine is less sensitive than cervical sampling in a population with abnormal cytology. Further exploration is warranted to determine clinical utility when other options are unavailable.

Indexed as

AdultAlphapapillomavirusBiopsyCervix UteriDNA Probes, HPVDNA, ViralEarly Detection of CancerFemaleGenotyping TechniquesHumansMiddle AgedSensitivity and SpecificityUterine Cervical NeoplasmsYoung AdultDNA Probes, HPVDNA, ViralCancer screeningCervical cancerHuman papillomavirusUrine samples

Identifiers

PMID24296266
PMCPMC4010249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.